Kodiak Sciences doses first patients in Phase 3 ALTO trial of KSI-501 for diabetic macular edema
Kodiak Sciences announced on 10 August 2026 that the first patients have been enrolled in its global Phase 3 ALTO trial evaluating KSI-501 in patients with diabetic macular edema (DME).
KSI-501 is an investigational, first-in-class bispecific therapy built on Kodiak's ABC Platform, designed to inhibit two complementary pathways implicated in retinal vascular disease: interleukin-6 (IL-6)-mediated inflammation and vascular endothelial growth factor (VEGF)-mediated vascular permeability and neovascularisation. The ALTO trial is designed to demonstrate the superiority of the bispecific (anti-VEGF, anti-IL-6) KSI-501 versus monospecific (anti-VEGF) aflibercept in DME, and evaluates two dosing regimens — one intensive and one with individualised dosing intervals of up to every six months.
ALTO is the second registrational Phase 3 trial of KSI-501, following the DAYBREAK study in wet age-related macular degeneration (AMD). The programme tests whether dual inhibition of the immune and vascular pathways can deliver deeper and more sustained disease control than anti-VEGF monotherapy for patients who continue to live with persistent retinal fluid and the burden of frequent injections.